Test urinaire PCA3, cancer de la prostate et autres pathologies prostatiques

Djavan, 2007, Biopsy standards for detection of prostate cancer, World J Urol, 25, 11, 10.1007/s00345-007-0151-1 Bussemakers, 1999, DD3: a new prostate-specific gene, highly overexpressed in prostate cancer, Cancer Res, 59, 5975 Hessels, 2009, The use of PCA3 in the diagnosis of prostate cancer, Nat Rev Urol, 6, 255, 10.1038/nrurol.2009.40 Balcerczak, 2003, Expression of p65, DD3 and c-erbB2 genes in prostate cancer, Neoplasma, 50, 97 Jung, 2003, DD3(PCA3)-based molecular urine analysis for the diagnosis of prostate cancer, Eur Urol, 44, 8, 10.1016/S0302-2838(03)00201-X Mearini, 2009, The combination of urine DD3(PCA3) mRNA and PSA mRNA as molecular markers of prostate cancer, Biomarkers, 14, 235, 10.1080/13547500902807306 Schalken, 2003, New targets for therapy in prostate cancer: differential display code 3 (DD3(PCA3)), a highly prostate cancer-specific gene, Urology, 62, 34, 10.1016/S0090-4295(03)00759-3 Hessels, 2003, DD3(PCA3)-based molecular urine analysis for the diagnosis of prostate cancer, Eur Urol, 44, 8, 10.1016/S0302-2838(03)00201-X Sokoll, 2008, A multicenter evaluation of the PCA3 molecular urine test: pre-analytical effects, analytical performance, and diagnostic accuracy, Clin Chim Acta, 389, 1, 10.1016/j.cca.2007.11.003 Groskopf, 2006, APTIMA PCA3 molecular urine test: development of a method to aid in the diagnosis of prostate cancer, Clin Chem, 52, 1089, 10.1373/clinchem.2005.063289 van Gils, 2007, The time-resolved fluorescence-based PCA3 test on urinary sediments after digital rectal examination; a Dutch multicenter validation of the diagnostic performance, Clin Cancer Res, 13, 939, 10.1158/1078-0432.CCR-06-2679 Vlaeminck-Guillem, 2010, Urinary prostate cancer 3 test: toward the age of reason?, Urology, 75, 447, 10.1016/j.urology.2009.03.046 Auprich, 2011, Contemporary role of prostate cancer antigen 3 in the management of prostate cancer, Eur Urol, 60, 1045, 10.1016/j.eururo.2011.08.003 Chun, 2009, Prostate Cancer Gene 3 (PCA3): development and internal validation of a novel biopsy nomogram, Eur Urol, 56, 659, 10.1016/j.eururo.2009.03.029 Ankerst, 2008, Predicting prostate cancer risk through incorporation of prostate cancer gene 3, J Urol, 180, 1303, 10.1016/j.juro.2008.06.038 Perdona, 2011, Prostate cancer detection in the “grey area” of prostate-specific antigen below 10ng/ml: head-to-head comparison of the updated PCPT calculator and Chun's nomogram, two risk estimators incorporating prostate cancer antigen 3, Eur Urol, 59, 81, 10.1016/j.eururo.2010.09.036 Vlaeminck-Guillem, 2011, Urinary PCA3 score predicts prostate cancer multifocality, J Urol, 185, 1234, 10.1016/j.juro.2010.11.072 Tosoian, 2010, Accuracy of PCA3 measurement in predicting short-term biopsy progression in an active surveillance program, J Urol, 183, 534, 10.1016/j.juro.2009.10.003 Marks, 2008, Prostate cancer specificity of PCA3 gene testing: examples from clinical practice, Rev Urol, 10, 175 de la Taille, 2011, Clinical evaluation of the PCA3 assay in guiding initial biopsy decisions, J Urol, 185, 2119, 10.1016/j.juro.2011.01.075 Popa, 2007, Identification of PCA3 (DD3) in prostatic carcinoma by in situ hybridization, Mod Pathol, 20, 1121, 10.1038/modpathol.3800963 Klecka, 2010, Differential display code 3 (DD3/PCA3) in prostate cancer diagnosis, Anticancer Res, 30, 665 Aubin, 2010, PCA3 molecular urine test for predicting repeat prostate biopsy outcome in populations at risk: validation in the placebo arm of the dutasteride REDUCE trial, J Urol, 184, 1947, 10.1016/j.juro.2010.06.098 Nyberg, 2010, PCA3 as a diagnostic marker for prostate cancer: a validation study on a Swedish patient population, Scand J Urol Nephrol, 44, 378, 10.3109/00365599.2010.521187 Ochiai, 2011, Prostate cancer gene 3 urine assay for prostate cancer in Japanese men undergoing prostate biopsy, Int J Urol, 18, 200, 10.1111/j.1442-2042.2010.02711.x Salami SS, Schmidt F, Laxman B, Regan MM, Rickman DS, Scherr D, et al. Combining urinary detection of TMPRSS2: ERG and PCA3 with serum PSA to predict diagnosis of prostate cancer. Urol Oncol 2011 doi:10.1016/j.urolonc.2011.04.001. Wang, 2009, Rational approach to implementation of prostate cancer antigen 3 into clinical care, Cancer, 115, 3879, 10.1002/cncr.24447 Haese, 2008, Clinical utility of the PCA3 urine assay in European men scheduled for repeat biopsy, Eur Urol, 54, 1081, 10.1016/j.eururo.2008.06.071 Tinzl, 2004, DD3PCA3 RNA analysis in urine – a new perspective for detecting prostate cancer, Eur Urol, 46, 182, 10.1016/j.eururo.2004.06.004 Remzi, 2010, Follow-up of men with an elevated PCA3 score and a negative biopsy: does an elevated PCA3 score indeed predict the presence of prostate cancer?, BJU Int, 106, 1138, 10.1111/j.1464-410X.2010.09330.x Deras, 2008, PCA3: a molecular urine assay for predicting prostate biopsy outcome, J Urol, 179, 1587, 10.1016/j.juro.2007.11.038 Galasso, 2010, PCA3: a new tool to diagnose prostate cancer (PCa) and a guidance in biopsy decisions. Preliminary report of the UrOP study, Arch Ital Urol Androl, 82, 5 Morote, 2010, Behavior of the PCA3 gene in the urine of men with high grade prostatic intraepithelial neoplasia, World J Urol, 28, 677, 10.1007/s00345-010-0580-0 Shappell, 2009, PCA3 urine mRNA testing for prostate carcinoma: patterns of use by community urologists and assay performance in reference laboratory setting, Urology, 73, 363, 10.1016/j.urology.2008.08.459 Klatte T, Waldert M, de Martino M, Schatzl G, Mannhalter C, Remzi M. Age-specific PCA3 score reference values for diagnosis of prostate cancer. World J Urol 2011, doi:10.1007/s00345-011-0749, PMID:21877172. Bialkowska-Hobrzanska, 2006, Expression of human telomerase reverse transcriptase, Survivin, DD3 and PCGEM1 messenger RNA in archival prostate carcinoma tissue, Can J Urol, 13, 2967 Clarke, 2009, New genomic structure for prostate cancer specific gene PCA3 within BMCC1: implications for prostate cancer detection and progression, PLoS One, 4, e4995, 10.1371/journal.pone.0004995 Neves, 2008, Combined analysis of multiple mRNA markers by RT-PCR assay for prostate cancer diagnosis, Clin Biochem, 41, 1191, 10.1016/j.clinbiochem.2008.06.013 Tao, 2010, PCA3 gene expression in prostate cancer tissue in a Chinese population: quantification by real-time FQ-RT-PCR based on exon 3 of PCA3, Exp Mol Pathol, 89, 58, 10.1016/j.yexmp.2010.01.008 de Kok, 2002, DD3(PCA3), a very sensitive and specific marker to detect prostate tumors, Cancer Res, 62, 2695 Floriano-Sanchez, 2009, DD3(PCA3) gene expression in cancer and prostatic hyperplasia, Clin Invest Med, 32, E258, 10.25011/cim.v32i6.10661 Landers, 2005, Use of multiple biomarkers for a molecular diagnosis of prostate cancer, Int J Cancer, 114, 950, 10.1002/ijc.20760 Marangoni, 2008, The -786T>C promoter polymorphism of the NOS3 gene is associated with prostate cancer progression, BMC Cancer, 8, 273, 10.1186/1471-2407-8-273 Marangoni, 2006, The endothelial nitric oxide synthase Glu-298-Asp polymorphism and its mRNA expression in the peripheral blood of patients with prostate cancer and benign prostatic hyperplasia, Cancer Detect Prev, 30, 7, 10.1016/j.cdp.2005.09.004 Auprich, 2010, External validation of urinary PCA3-based nomograms to individually predict prostate biopsy outcome, Eur Urol, 8, 727, 10.1016/j.eururo.2010.06.038 Marks, 2007, PCA3 molecular urine assay for prostate cancer in men undergoing repeat biopsy, Urology, 69, 532, 10.1016/j.urology.2006.12.014 Rigau, 2010, PSGR and PCA3 as biomarkers for the detection of prostate cancer in urine, Prostate, 70, 1760, 10.1002/pros.21211 Adam, 2011, The role of the PCA3 assay in predicting prostate biopsy outcome in a South African setting, BJU Int, 108, 1728, 10.1111/j.1464-410X.2011.10202.x Shen, 2011, The diagnostic value of PCA3 gene-based analysis of urine sediments after digital rectal examination for prostate cancer in a Chinese population, Exp Mol Pathol, 90, 97, 10.1016/j.yexmp.2010.10.009 Talesa, 2009, Diagnostic potential in prostate cancer of a panel of urinary molecular tumor markers, Cancer Biomark, 5, 241, 10.3233/CBM-2009-0109 Henderson, 2010, The role of PCA3 testing in patients with a raised prostate-specific antigen level after Greenlight photoselective vaporization of the prostate, J Endourol, 24, 1821, 10.1089/end.2010.0196 Aubin, 2011, Prostate cancer Gene 3 score predicts prostate biopsy outcome in men receiving dutasteride for prevention of prostate cancer: results from the REDUCE Trial, Urology, 78, 380, 10.1016/j.urology.2011.03.033 van Gils, 2009, Preliminary evaluation of the effect of dutasteride on PCA3 in post-DRE urine sediments: a randomized, open-label, parallel-group pilot study, Prostate, 69, 1624, 10.1002/pros.21011 Andriole, 2010, Effect of dutasteride on the risk of prostate cancer, N Engl J Med, 362, 1192, 10.1056/NEJMoa0908127 Roehrborn, 2011, Dutasteride improves outcomes of benign prostatic hyperplasia when evaluated for prostate cancer risk reduction: secondary analysis of the REduction by Dutasteride of Prostate Cancer Events (REDUCE) Trial, Urology, 78, 641, 10.1016/j.urology.2011.03.063 Vlaeminck-Guillem, 2011, Chronic prostatitis does not influence urinary PCA3 score, Prostate, 72, 549, 10.1002/pros.21457